Jubilant Pharmova Expands U.S. Injectable Capacity with New Sterile Fill & Finish Line

Jubilant Pharmova Expands U.S. Injectable Capacity with New Sterile Fill & Finish Line

By, Admin 11 October 2025

Jubilant Pharmova’s contract manufacturing arm, Jubilant HollisterStier (JHS), has launched its third Sterile Fill & Finish line at the Spokane Manufacturing Facility in Washington, U.S.—a major leap in its North American expansion strategy.

A Milestone in Expansion

The new line has already produced its first commercial batch, marking the start of revenue generation. This addition boosts capacity by 50%, moving JHS closer to doubling its total sterile injectable output once the fourth line goes live.

Advanced Tech and Regulatory Strength

  • Equipped with next-gen isolator technology for superior sterility, precision, and efficiency.
  • Designed to meet stringent global regulatory standards (U.S. FDA, EMA, PMDA Japan, Health Canada, ANVISA, etc.).
  • Backed by a US$132 million investment, reflecting JHS’s commitment to innovation, quality, and supply chain resilience.

Strengthening U.S. Supply Chain

The expansion comes as global pharma companies seek reliable U.S.-based manufacturing partners, especially amid new tariff policies. By enhancing domestic capacity, JHS is helping reduce offshore dependency and strengthen U.S. health security.

“With the third line operational and the fourth on the way, we’re not just doubling capacity — we’re building a future of resilient, high-quality U.S. manufacturing,”

  • Chris Preti, CEO – CDMO Sterile Injectables, Jubilant HollisterStier.

Market Traction and Trust

  • Growing RFP demand from large innovator pharma companies.
  • Expected full utilization in three years.
  • 92% customer retention rate and partnerships with 5 of the top 20 global pharma players.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!